Measurement of disease activity in psoriatic arthritis -: Extended report

被引:16
作者
Ujfalussy, I [1 ]
Koó, É [1 ]
机构
[1] Polyclin Hosp Brothers St John God, Dept Rheumatol 2, H-1023 Budapest, Hungary
来源
ZEITSCHRIFT FUR RHEUMATOLOGIE | 2003年 / 62卷 / 01期
关键词
psoriatic arthritis; measurement; disease activity; improvement criteria;
D O I
10.1007/s00393-003-0455-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To determine whether activity indices, generally accepted in rheumatoid arthritis (RA) are useful and valid to measure disease activity in psoriatic arthritis (PsA) patients with peripheral arthritis. Methods 38 PsA patients were studied before and after a one year DMARD treatment. Extended and reduced tender and swollen joint counts, Ritchie articular index, Health Assessment Questionnaire (HAQ) score, erythrocyte sedimentation rate (ESR) morning stiffness, the patient's and the assessor's global assessment (PGA and AGA) were recorded. Disease activity scores, EULAR, ACR and Clegg improvement criteria were calculated. Results All indices correlated well before and after treatment with AGA (r > 0.337, p < 0.042), except morning stiffness and tender joint counts. After treatment, PGA correlated well only with the 68 and 28 tender joint counts, ESR and HAQ (r > 0.340, p < 0.05). The response to DMARD treatment was well characterized with the changes in the number of tender and swollen joint counts, and DAS4, DAS3, DAS28. The changes correlated with the PGA and AGA. The level of agreement between Clegg and the EULAR improvement criteria with both extended and reduced joint count was comparable (p < 0.01). Conclusion The well-known activity indices generally accepted in RA, as tender and swollen joint count, DAS3, DAS4, DAS28, are useful and valid indices measuring arthritis activity in PsA with peripheral arthritis. The correlation between Clegg and EULAR improvement classification indices were similar. Both seemed to characterize changes authenticated during DMARD treatment.
引用
收藏
页码:60 / 65
页数:6
相关论文
共 20 条
[1]  
BLACKMORE MG, 1995, J RHEUMATOL, V22, P886
[2]   Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis - A Department of Veterans Affairs cooperative study [J].
Clegg, DO ;
Reda, DJ ;
Mejias, E ;
Cannon, GW ;
Weisman, MH ;
Taylor, T ;
BudimanMak, E ;
Blackburn, WD ;
Vasey, FB ;
Mahowald, ML ;
Cush, JJ ;
Schumacher, HR ;
Silverman, SL ;
Alepa, FP ;
Luggen, ME ;
Cohen, MR ;
Makkena, R ;
Haakenson, CM ;
Ward, RH ;
Manaster, BJ ;
Anderson, RJ ;
Ward, JR ;
Henderson, WG .
ARTHRITIS AND RHEUMATISM, 1996, 39 (12) :2013-2020
[3]   Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis - A Department of Veterans Affairs cooperative study [J].
Clegg, DO ;
Reda, DJ ;
Weisman, MH ;
Blackburn, WD ;
Cush, JJ ;
Cannon, GW ;
Mahowald, ML ;
Schumacher, HR ;
Taylor, T ;
BudimanMak, E ;
Cohen, MR ;
Vasey, FB ;
Luggen, ME ;
Mejias, E ;
Silverman, SL ;
Makkena, R ;
Alepa, FP ;
Buxbaum, J ;
Haakenson, CM ;
Ward, RH ;
Manaster, BJ ;
Anderson, RJ ;
Ward, JR ;
Henderson, WG .
ARTHRITIS AND RHEUMATISM, 1996, 39 (12) :2004-2012
[4]   THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY PRELIMINARY CORE SET OF DISEASE-ACTIVITY MEASURES FOR RHEUMATOID-ARTHRITIS CLINICAL-TRIALS [J].
FELSON, DT ;
ANDERSON, JJ ;
BOERS, M ;
BOMBARDIER, C ;
CHERNOFF, M ;
FRIED, B ;
FURST, D ;
GOLDSMITH, C ;
KIESZAK, S ;
LIGHTFOOT, R ;
PAULUS, H ;
TUGWELL, P ;
WEINBLATT, M ;
WIDMARK, R ;
WILLIAMS, HJ ;
WOLFE, F .
ARTHRITIS AND RHEUMATISM, 1993, 36 (06) :729-740
[5]  
FELSON DT, 1995, ARTHRITIS RHEUM, V38, P327
[6]  
GARRETT S, 1994, J RHEUMATOL, V21, P2286
[7]  
Gladman DD, 2001, J RHEUMATOL, V28, P1045
[8]  
GLADMAN DD, 1990, J RHEUMATOL, V17, P62
[9]  
GOLDSMITH CH, 1993, J RHEUMATOL, V20, P552
[10]   CYTIDINE DEAMINASE ACTIVITY, C-REACTIVE-PROTEIN, HISTIDINE, AND ERYTHROCYTE SEDIMENTATION-RATE AS MEASURES OF DISEASE-ACTIVITY IN PSORIATIC-ARTHRITIS [J].
HELLIWELL, PS ;
MARCHESONI, A ;
PETERS, M ;
PLATT, R ;
WRIGHT, V .
ANNALS OF THE RHEUMATIC DISEASES, 1991, 50 (06) :362-365